Literature DB >> 12707379

5'-(RACE) identification of rare ALK fusion partner in anaplastic large cell lymphoma.

N Scott Reading1, Stephen D Jenson, Jeffrey K Smith, Megan S Lim, Kojo S J Elenitoba-Johnson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12707379      PMCID： PMC1907320          DOI： 10.1016/S1525-1578(10)60463-1

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN： 1525-1578            Impact factor:   5.568


× No keyword cloud information.
  26 in total

Review 1.  Alk+ CD30+ lymphomas: a distinct molecular genetic subtype of non-Hodgkin's lymphoma.

Authors:  S W Morris; L Xue; Z Ma; M C Kinney
Journal:  Br J Haematol       Date:  2001-05       Impact factor: 6.998

2.  TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors.

Authors:  B Lawrence; A Perez-Atayde; M K Hibbard; B P Rubin; P Dal Cin; J L Pinkus; G S Pinkus; S Xiao; E S Yi; C D Fletcher; J A Fletcher
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

3.  A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma.

Authors:  M Trinei; L Lanfrancone; E Campo; K Pulford; D Y Mason; P G Pelicci; B Falini
Journal:  Cancer Res       Date:  2000-02-15       Impact factor: 12.701

4.  ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35).

Authors:  G W Colleoni; J A Bridge; B Garicochea; J Liu; D A Filippa; M Ladanyi
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

5.  Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis.

Authors:  Z Ma; J Cools; P Marynen; X Cui; R Siebert; S Gesk; B Schlegelberger; B Peeters; C De Wolf-Peeters; I Wlodarska; S W Morris
Journal:  Blood       Date:  2000-03-15       Impact factor: 22.113

6.  The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997.

Authors:  N L Harris; E S Jaffe; J Diebold; G Flandrin; H K Muller-Hermelink; J Vardiman; T A Lister; C D Bloomfield
Journal:  Ann Oncol       Date:  1999-12       Impact factor: 32.976

7.  Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors.

Authors:  C A Griffin; A L Hawkins; C Dvorak; C Henkle; T Ellingham; E J Perlman
Journal:  Cancer Res       Date:  1999-06-15       Impact factor: 12.701

8.  Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma.

Authors:  R D Gascoyne; P Aoun; D Wu; M Chhanabhai; B F Skinnider; T C Greiner; S W Morris; J M Connors; J M Vose; D S Viswanatha; A Coldman; D D Weisenburger
Journal:  Blood       Date:  1999-06-01       Impact factor: 22.113

9.  Lymphomas expressing ALK fusion protein(s) other than NPM-ALK.

Authors:  B Falini; K Pulford; A Pucciarini; A Carbone; C De Wolf-Peeters; J Cordell; M Fizzotti; A Santucci; P G Pelicci; S Pileri; E Campo; G Ott; G Delsol; D Y Mason
Journal:  Blood       Date:  1999-11-15       Impact factor: 22.113

10.  TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations.

Authors:  L Hernández; M Pinyol; S Hernández; S Beà; K Pulford; A Rosenwald; L Lamant; B Falini; G Ott; D Y Mason; G Delsol; E Campo
Journal:  Blood       Date:  1999-11-01       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.